Home / Stocks / ARQT

Arcutis Biotherapeutics (ARQT, Biotech) Stock Valuation & Fair Value

No P/E valuation

Arcutis Biotherapeutics (ARQT, Biotech) trades at a current P/E of 74.5, trading without a historical P/E to compare against, with a forward growth estimate above 100% and a PEG of 0.63. Analysts' one-year estimates have been hit 20% of the time.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

This company has no P/E to compare against its own history, so tickerseer publishes no valuation rating for it. The figures below are unaffected.

DATA AS OF 2026-11-07
Current P/E
74.5
Normal P/E
—
PEG
0.63
Fwd growth
>100%
Div yield
0.0%
RSI (14)
38.6
Neutral
Technical context
  • Price $25.55 at the Nov 6 close, 15.6% below the 20-day average ($30.27) and 5.9% below the 50-day ($27.16).
  • RSI (14) at 38.6.
  • 52-week range $19.50 to $34.05: the price is 25.0% below the high and 31.0% above the low.

The Street vs SeerForecast

Wall Street's mean price target for ARQT is $39.12 across 8 analysts, 53.1% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: we publish none, because it has no P/E to compare against its own history. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer has published no valuation rating since 2026-07-31, because this company has no P/E to compare against its own history.

Current P/E and rating by weekCurrent P/E moved from 439.7 to 93.5 between 2026-07-31 and 2026-10-30, with 0 rating changes over 14 recorded weeks.2026-07-31: P/E 439.7, No P/E valuation, recalculated for the week of 2026-07-312026-07-31: P/E 415.9, No P/E valuation, recorded live 2026-08-032026-08-07: P/E 415.9, No P/E valuation, recalculated for the week of 2026-08-072026-08-07: P/E 112.9, No P/E valuation, recorded live 2026-08-102026-08-14: P/E 112.9, No P/E valuation, recalculated for the week of 2026-08-142026-08-14: P/E 439.7, No P/E valuation, recorded live 2026-08-172026-08-21: P/E 439.7, No P/E valuation, recalculated for the week of 2026-08-212026-08-21: P/E 101.7, No P/E valuation, recorded live 2026-08-242026-08-27: P/E 101.7, No P/E valuation, recalculated for the week of 2026-08-272026-08-28: P/E 101.7, No P/E valuation, recalculated for the week of 2026-08-282026-08-28: P/E 101.7, No P/E valuation, recalculated for the week of 2026-08-302026-08-28: P/E 92.2, No P/E valuation, recorded live 2026-08-312026-09-04: P/E 92.2, No P/E valuation, recalculated for the week of 2026-09-052026-09-04: P/E 88.8, No P/E valuation, recorded live 2026-09-072026-09-11: P/E 88.8, No P/E valuation, recalculated for the week of 2026-09-122026-09-11: P/E 85.1, No P/E valuation, recorded live 2026-09-142026-09-18: P/E 85.1, No P/E valuation, recalculated for the week of 2026-09-192026-09-18: P/E 82.9, No P/E valuation, recorded live 2026-09-212026-09-25: P/E 82.9, No P/E valuation, recalculated for the week of 2026-09-262026-09-25: P/E 84.7, No P/E valuation, recorded live 2026-09-282026-10-02: P/E 84.7, No P/E valuation, recalculated for the week of 2026-10-032026-10-02: P/E 76.3, No P/E valuation, recorded live 2026-10-052026-10-09: P/E 76.3, No P/E valuation, recalculated for the week of 2026-10-102026-10-09: P/E 85.6, No P/E valuation, recorded live 2026-10-122026-10-16: P/E 85.6, No P/E valuation, recalculated for the week of 2026-10-172026-10-16: P/E 89.7, No P/E valuation, recorded live 2026-10-192026-10-23: P/E 93.9, No P/E valuation, recorded live 2026-10-262026-10-30: P/E 93.9, No P/E valuation, recalculated for the week of 2026-10-312026-10-30: P/E 93.5, No P/E valuation, recorded live 2026-11-02100.0200.0300.0400.0Jul 31Aug 23Sep 15Oct 7Oct 30
No P/E valuationNo P/E valuation

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-07-31P/E 439.7not availableNo P/E valuation (recalculated)
2026-10-05P/E 76.3not availableNo P/E valuation
2026-11-02P/E 93.5not availableNo P/E valuation ← now
Show all 29 readings
WeekCurrent P/EPremium to normal P/ERating
2026-07-31P/E 439.7not availableNo P/E valuation (recalculated)
2026-08-03P/E 415.9not availableNo P/E valuation
2026-08-07P/E 415.9not availableNo P/E valuation (recalculated)
2026-08-10P/E 112.9not availableNo P/E valuation
2026-08-14P/E 112.9not availableNo P/E valuation (recalculated)
2026-08-17P/E 439.7not availableNo P/E valuation
2026-08-21P/E 439.7not availableNo P/E valuation (recalculated)
2026-08-24P/E 101.7not availableNo P/E valuation
2026-08-27P/E 101.7not availableNo P/E valuation (recalculated)
2026-08-28P/E 101.7not availableNo P/E valuation (recalculated)
2026-08-30P/E 101.7not availableNo P/E valuation (recalculated)
2026-08-31P/E 92.2not availableNo P/E valuation
2026-09-05P/E 92.2not availableNo P/E valuation (recalculated)
2026-09-07P/E 88.8not availableNo P/E valuation
2026-09-12P/E 88.8not availableNo P/E valuation (recalculated)
2026-09-14P/E 85.1not availableNo P/E valuation
2026-09-19P/E 85.1not availableNo P/E valuation (recalculated)
2026-09-21P/E 82.9not availableNo P/E valuation
2026-09-26P/E 82.9not availableNo P/E valuation (recalculated)
2026-09-28P/E 84.7not availableNo P/E valuation
2026-10-03P/E 84.7not availableNo P/E valuation (recalculated)
2026-10-05P/E 76.3not availableNo P/E valuation
2026-10-10P/E 76.3not availableNo P/E valuation (recalculated)
2026-10-12P/E 85.6not availableNo P/E valuation
2026-10-17P/E 85.6not availableNo P/E valuation (recalculated)
2026-10-19P/E 89.7not availableNo P/E valuation
2026-10-26P/E 93.9not availableNo P/E valuation
2026-10-31P/E 93.9not availableNo P/E valuation (recalculated)
2026-11-02P/E 93.5not availableNo P/E valuation ← now

Frequently asked questions

Is Arcutis Biotherapeutics stock overvalued?

At a current P/E of 74.5, Arcutis Biotherapeutics has no historical normal P/E on record to compare that against, with a PEG of 0.63 on forward growth above 100%. tickerseer therefore publishes no valuation rating for it.

What is Arcutis Biotherapeutics's fair value and PEG?

Arcutis Biotherapeutics trades at a current P/E of 74.5, a PEG of 0.63, and a forward growth estimate above 100%.

Has tickerseer's rating of Arcutis Biotherapeutics changed?

tickerseer has published no valuation rating since 2026-07-31, because this company has no P/E to compare against its own history.

What is the analyst price target for Arcutis Biotherapeutics?

The mean Wall Street price target for Arcutis Biotherapeutics is $39.12 across 8 analysts, 53.1% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotech. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track ARQT free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.